Skip to content
Screener

Syndax Pharmaceuticals SNDX Short-Term Investments

Short-Term Investments at other companies

Biogen logo
BiogenBIIB
$0
Kura Oncology logo
Kura OncologyKURA
$541.74M-10.7%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$264.28M+109%
Nuvation Bio logo
Nuvation BioNUVB
$402.35M+11.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$816.54M+83.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$552M-16.7%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.76B+58.9%
Enterprise value$1.98B+48.9%
P/S8.1×-6.1×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
Line itemMarch 31, 2026December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents$130,893$134,930
Short-term investments221,171259,140
Accounts receivable38,11637,996
Inventory, net34,94832,754
Short-term deposits9,17519,616
Other receivables, net2676,404

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's short-term investments?
Syndax Pharmaceuticals (SNDX) reported short-term investments of $221.17M in Q1 2026.
How has Syndax Pharmaceuticals's short-term investments changed year-over-year?
Syndax Pharmaceuticals's short-term investments decreased by 38.3% year-over-year, from $358.2M to $221.17M.
What is the long-term trend for Syndax Pharmaceuticals's short-term investments?
Over 5 years (2020 to 2025), Syndax Pharmaceuticals's short-term investments has grown at a 7.8% compound annual growth rate (CAGR), from $177.82M to $259.14M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Syndax Pharmaceuticals's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude